Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform.
Lotz GP, Benstein K, Bloem K, Buddiger H, Calonder C, Elm S, Fernandez E, Goodman J, Gorovits B, Grudzinska-Goebel J, Janssen M, Jawa V, Kramer D, Luo L, Malisauskas M, Michaut L, Schäfer M, Spindeldreher S, Ullmann M, Nana Weldingh K, Kromminga A, Snoeck V. Lotz GP, et al. Among authors: spindeldreher s. AAPS J. 2022 May 12;24(3):68. doi: 10.1208/s12248-022-00712-2. AAPS J. 2022. PMID: 35554731
10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.
Tourdot S, Abdolzade-Bavil A, Bessa J, Broët P, Fogdell-Hahn A, Giorgi M, Jawa V, Kuranda K, Legrand N, Pattijn S, Pedras-Vasconcelos JA, Rudy A, Salmikangas P, Scott DW, Snoeck V, Smith N, Spindeldreher S, Kramer D. Tourdot S, et al. Among authors: spindeldreher s. MAbs. 2020 Jan-Dec;12(1):1725369. doi: 10.1080/19420862.2020.1725369. MAbs. 2020. PMID: 32063088 Free PMC article.
Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.
van der Weele L, Pollastro S, van Schaik BDC, van Kampen AHC, Niewold ITG, Kuijpers TW, Warnke C, Jensen PEH, Kramer D, Ryner M, Hermanrud C, Dönnes P, Pallardy M, Spindeldreher S, Deisenhammer F, Fogdell-Hahn A, de Vries N; ABIRISK Consortium. van der Weele L, et al. Among authors: spindeldreher s. J Neuroimmunol. 2022 Sep 15;370:577932. doi: 10.1016/j.jneuroim.2022.577932. Epub 2022 Jul 14. J Neuroimmunol. 2022. PMID: 35853357 Free article.
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.
Tourdot S, Baltrunkonis D, Denies S, Devanarayan V, Grudzinska-Goebel J, Kromminga A, Lotz GP, Malherbe L, Michaut L, Weldingh KN, Pedras-Vasconcelos JA, Salazar-Fontana LI, Spindeldreher S, Sauna Z, Snoeck V, Verthelyi D, Kramer D. Tourdot S, et al. Among authors: spindeldreher s. MAbs. 2024 Jan-Dec;16(1):2324801. doi: 10.1080/19420862.2024.2324801. Epub 2024 Mar 5. MAbs. 2024. PMID: 38441119 Free PMC article.
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies.
Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, Muller PY, Frings W, Sims J. Brennan FR, et al. Among authors: spindeldreher s. MAbs. 2010 May-Jun;2(3):233-55. doi: 10.4161/mabs.2.3.11782. Epub 2010 May 23. MAbs. 2010. PMID: 20421713 Free PMC article. Review.
30 results